Technetium-99m NM 01 diagnostic - NanoMab
Alternative Names: 99m-Tc-NM-01; 99mTC-NM-01; 99mTC-NM-01 - Lantheus Holdings/NanoMabLatest Information Update: 19 Sep 2023
At a glance
- Originator NanoMab
- Class Antibodies; Diagnostic agents; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-small cell lung cancer
Most Recent Events
- 13 Jul 2023 Technetium-99m NM 01 diagnostic licensed to Lantheus Holdings
- 13 Jul 2023 NanoMab has patent pending for "Anti-PD-L1 nanobody, coding sequence and use thereof" in the Europe and Multiple countries worldwide (before July 2023)
- 13 Jul 2023 NanoMab has patent protection for "Anti-PD-L1 nanobody, coding sequence and use thereof" in the US and China (before July 2023)